ARTV Stock Surges Over 93% After FDA Fast Track Designation

Artiva Biotherapeutics (NASDAQ:ARTV) stock experienced a dramatic surge of over 93% on Friday, October 17, 2025, following the announcement of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for its AlloNK cell therapy candidate in combination with rituximab for treating refractory rheumatoid arthritis. This marks the first time this deep B-cell depleting therapy has received this designation for refractory rheumatoid arthritis, a condition affecting over 100,000 U.S. patients who haven’t responded to traditional treatments like methotrexate and TNF inhibitors.